Department of Pediatric Infectious Diseases, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey. Correspondence to: Dr Selin Tasar, Department of Pediatric Infectious Diseases, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey.
Department of Pediatric Infectious Diseases, University of Health Sciences, Tepecik Training and Research Hospital, Izmir, Turkey.
Indian Pediatr. 2023 Mar 15;60(3):217-220. doi: 10.1007/s13312-023-2838-1.
The aim of this study was to determine the availability of serum amyloid A (SAA) in the diagnosis of coronavirus disease 2019 (COVID-19), to asses disease severity and to predict hospitalization status.
Between March, 2020 and March, 2021, a total of 80 children (40 cases with COVID-19 and 40 cases in healthy group) were included in this study. Patients were divided into two groups (mild and moderate/severe) to evaluate SAA levels in terms of clinical severity and also hospitalization status.
Comparisons between the two groups revealed that median SAA values were significantly higher in children with COVID-19 than in their healthy peers (21.45vs3.05 mg/L, P=0.002). There was no significant difference in the median serum SAA levels between mild and moderate/severe clinical disease (P=0.837). The SAA difference between the two groups with regards to hospitalization was not statistically significant (P=0.098).
Although SAA level was found to be higher in children with COVID 19 compared to healthy controls, the sensitivity of SAA for the disease was found to be low. In addition, there was no difference between the groups in terms of clinical severity.
本研究旨在确定血清淀粉样蛋白 A（SAA）在 2019 冠状病毒病（COVID-19）诊断中的可用性，评估疾病严重程度并预测住院状态。
本研究共纳入 80 例儿童（40 例 COVID-19 患儿和 40 例健康对照组），时间为 2020 年 3 月至 2021 年 3 月。根据临床严重程度将患者分为两组（轻症和中/重症），并评估 SAA 水平与住院状态的关系。
两组比较显示，COVID-19 患儿的 SAA 中位数显著高于健康对照组（21.45vs3.05mg/L，P=0.002）。轻症和中/重症患儿的血清 SAA 水平中位数无显著差异（P=0.837）。两组间关于住院的 SAA 差异无统计学意义（P=0.098）。
尽管 COVID-19 患儿的 SAA 水平高于健康对照组，但 SAA 对疾病的敏感性较低。此外，两组在临床严重程度方面无差异。
